PRODUCTS
Trading
Tools
PLATFORMS
PRICING
PROMOTION
LEARN
HUB
More from Webull
- About us
Our Partners
- Wall Street Journal
SUPPORT

IMMX

Immix Biopharma Inc

1.97

-0.13-6.19%

After Hours: 2.009 +0.039 +1.97%17:29 09/06 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE2.110/2.100

TODAY RANGE1.950-2.140

VOL147.52K

MARKET CAP54.08M

52 WEEK RANGE1.550-7.75

AVG VOL (3M)157.17K

% TURNOVER0.54%

TURNOVER--

P/E (TTM)-2.3422

% RANGE7.62%

EPS(TTM)-0.8411

P/E(FORWARD)-2.2386

P/B2.262

BVPS0.8710

DIVIDEND--

P/S--

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP30.28M

SHARES OUTSTANDING27.45M

NEXT EARNINGS11/09-11/13

FREE FLOAT15.37M

LOT SIZE1

EX-DIV DATE--

News

Press Releases

Financial Reports

Profile

Latest

Popular

Reuters·08/28 13:32
IMMIX BIOPHARMA EXPANDS U.S. CLINICAL SITES FOR RELAPSED/REFRACTORY AL AMYLOIDOSIS TRIAL NEXICART-2
NASDAQ·08/19 16:00
What Makes Immix Biopharma (IMMX) a New Buy Stock
Dow Jones·08/19 12:42
Immix Biopharma Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Benzinga·08/19 12:32
HC Wainwright & Co. Reiterates Buy on Immix Biopharma, Maintains $7 Price Target
TipRanks·08/19 10:40
Analysts Offer Insights on Healthcare Companies: Equillium (EQ), Foghorn Therapeutics (FHTX) and Immix Biopharma, Inc. (IMMX)
Reuters·08/13 19:18
Immix Biopharma Inc reports results for the quarter ended in June - Earnings Summary
Investorplace·08/13 02:52
IMMX Stock Earnings: Immix Biopharma Beats EPS for Q2 2024
Press release·08/12 23:13
Based on the provided financial report articles, I generated the title for the article: **Consolidated Balance Sheets and Statements of Changes in Equity for the Quarter Ended June 30, 2024** Please note that the title is generated based on the content provided, and it may not be the exact title used in the original article.
Dow Jones·07/26 11:07
Immix Biopharma Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Benzinga·07/26 11:00
HC Wainwright & Co. Reiterates Buy on Immix Biopharma, Maintains $7 Price Target
TipRanks·07/26 10:26
Buy Rating Affirmed: NXC-201’s Promising Clinical Trials and Strategic CIRM Grant Propel Positive Outlook
Benzinga·07/26 05:41
Reported Earlier, Immix Biopharma Secures $8M Funding From California Institute For Regenerative Medicine For CAR-T NXC-201 Trial In AL Amyloidosis
Reuters·07/26 01:31
CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE AWARDS FUNDING FOR CAR-T NXC-201 U.S. AL AMYLOIDOSIS CLINICAL TRIAL (NEXICART-2)
TipRanks·07/09 10:16
Buy Rating Affirmed for Immix Biopharma Amid Promising NXC-201 Trial Outcomes and Market Potential
Seeking Alpha·07/08 18:04
Immix Biopharma doses first patient in U.S. AL amyloidosis trial

Same Industry

Name/Symbol

Change%

Price

McKesson

MCK

-2.06%

504.17

Biogen Inc

BIIB

-0.49%

200.81

Amgen Inc

AMGN

-1.17%

320.56

Shire

SHPG

179.20

Bristol-Myers Squibb Company Celegne Contingent Value Rights

CELG-RT

0.00%

0.0405

Lilly Eli & Co

LLY

-1.10%

902.71

Celgene

CELG

108.24

Therapeuticsmd Inc

TXMD

-2.81%

1.730

Johnson & Johnson

JNJ

-0.37%

164.38

Abbvie Inc

ABBV

+0.28%

193.40

Zoetis Inc

ZTS

+1.41%

189.23

Gilead Sciences Inc

GILD

-0.06%

78.72

Novo-Nordisk A/S

NVO

+0.19%

131.14

Bristol-Myers Squibb Co

BMY

-2.21%

48.70

Alexion Pharms

ALXN

+1.70%

182.50

Pfizer

PFE

+0.18%

28.56

Sanofi FR

SNY

-0.88%

57.73

Sanofi FR

GCVRZ

0.00%

0.8711

Novartis

NVS

+0.14%

116.65

Dr Reddys Labs

RDY

-0.55%

79.20